Retrospective Analysis of Medical Costs and Length of Initial Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation (ICBMT 2025) - Sep 3, 2025 - Abstract #OP07-5; Pres time: Sep 12, 2025; 09:40 AM - 09:50 AM; "These values were log-transformed, and multiple regression analyses were performed using the following explanatory variables: year of HSCT, recipient age, recipient sex, diagnosis, disease risk, number of transplantation procedures, donor source, performance status, HCT-CI, conditioning intensity, engraftment failure, ICU admission, acute GVHD (grade III–IV), VOD/SOS, relapse during hospitalization, and use of letermovir... In CB and Haplo transplantations, delayed hematopoietic recovery, extended need for blood transfusion, and infection prophylaxis contributed to increased medical costs. The recent use of novel agents for acute GVHD, VOD/SOS, and CMV prophylaxis may have contributed to increased medical costs. Keywords: Medical costs, Hematopoietic stem cell transplantation"
HEOR • Retrospective data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Transplantation
|
|
Ayako Takarada 1; Naoki Kurita 2, 3; Ryota Ishii 4; Fumiaki Matsumura 3; Kenichi Makishima 3; Sakurako Suma 3; Yuya Sasaki 3; Yasuhito Suehara 2, 3; Keiichiro Hattori 2, 3; Tatsuhiro Sakamoto 2, 3; Takayasu Kato 2, 3; Naoshi Obara 2, 3; Shigeru Chiba 2, 3; Hidekazu Nishikii 2, 3; Mamiko Sakata-Yanagimoto 2, 3
|